MX374290B - Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer. - Google Patents
Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer.Info
- Publication number
- MX374290B MX374290B MX2016005801A MX2016005801A MX374290B MX 374290 B MX374290 B MX 374290B MX 2016005801 A MX2016005801 A MX 2016005801A MX 2016005801 A MX2016005801 A MX 2016005801A MX 374290 B MX374290 B MX 374290B
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- btk inhibitor
- cancer
- treatment
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a la terapia de combinación de un anticuerpo anti-CD20 con un inhibidor de BTK para el tratamiento del cáncer, especialmente a la terapia de combinación de cánceres que expresan CD20 con un anticuerpo anti-CD20 de tipo I o un anticuerpo B-Ly1 humanizado afucosilado y un inhibidor de BTK.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192006 | 2013-11-07 | ||
| PCT/EP2014/073640 WO2015067586A2 (en) | 2013-11-07 | 2014-11-04 | Combination therapy of an anti cd20 antibody with a btk inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016005801A MX2016005801A (es) | 2016-11-29 |
| MX374290B true MX374290B (es) | 2025-03-06 |
Family
ID=49552219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016005801A MX374290B (es) | 2013-11-07 | 2014-11-04 | Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20150125446A1 (es) |
| EP (1) | EP3066126B1 (es) |
| JP (1) | JP6478989B2 (es) |
| KR (1) | KR101874215B1 (es) |
| CN (3) | CN113995843A (es) |
| AR (1) | AR098328A1 (es) |
| AU (1) | AU2014345712B2 (es) |
| CA (1) | CA2926893C (es) |
| ES (1) | ES2728350T3 (es) |
| HK (1) | HK1222803A1 (es) |
| IL (1) | IL244960B (es) |
| MX (1) | MX374290B (es) |
| MY (1) | MY178726A (es) |
| NZ (1) | NZ718792A (es) |
| PH (1) | PH12016500839A1 (es) |
| PL (1) | PL3066126T3 (es) |
| RU (1) | RU2727650C2 (es) |
| TR (1) | TR201907240T4 (es) |
| TW (1) | TWI524899B (es) |
| WO (1) | WO2015067586A2 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2544719T (lt) | 2010-03-12 | 2019-10-25 | Debiopharm Int Sa | Cd37 surišančios molekulės, ir jų imunokonjugatai |
| US8940725B2 (en) | 2010-05-31 | 2015-01-27 | Ono Pharmaceutical Co., Ltd. | Purinone derivative |
| BR112014012727B1 (pt) | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
| WO2015146159A1 (en) * | 2014-03-25 | 2015-10-01 | Ono Pharmaceutical Co., Ltd. | Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma |
| CA2979671C (en) * | 2014-09-23 | 2020-03-10 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
| JP6750613B2 (ja) | 2015-04-09 | 2020-09-02 | 小野薬品工業株式会社 | プリノン誘導体の製造方法 |
| BR112017026027A2 (pt) | 2015-06-08 | 2018-08-14 | Debiopharm Int Sa | combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20 |
| AU2016282334B2 (en) | 2015-06-24 | 2022-07-21 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| AU2016304172A1 (en) * | 2015-08-03 | 2018-03-15 | Gilead Sciences, Inc. | Combination therapies for treating cancers |
| JP6890581B2 (ja) | 2015-08-28 | 2021-06-18 | デビオファーム インターナショナル, エス. アー. | Cd37の検出のための抗体およびアッセイ |
| ES2900482T3 (es) * | 2015-10-01 | 2022-03-17 | Gilead Sciences Inc | Combinación de un inhibidor de Btk y un inhibidor de punto de control para el tratamiento del cáncer |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| MX2018003822A (es) | 2015-10-02 | 2018-06-22 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso. |
| EP3355871A1 (en) * | 2015-10-02 | 2018-08-08 | Gilead Sciences, Inc. | Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases |
| US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
| CA3045944A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| JP2020528061A (ja) * | 2017-07-26 | 2020-09-17 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法 |
| AU2018314765C1 (en) | 2017-08-08 | 2025-11-20 | Bruker Spatial Biology, Inc. | Obinutuzumab treatment of a DLBCL patient subgroup |
| AU2019277836A1 (en) | 2018-05-30 | 2021-01-21 | Debiopharm International, S.A. | Anti-CD37 immunoconjugate dosing regimens |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2021170045A1 (en) * | 2020-02-27 | 2021-09-02 | Beigene Switzerland Gmbh | Methods of treating dlbcl using btk inhibitors and combinations thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999029888A1 (en) * | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| KR100944575B1 (ko) * | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| US7312243B1 (en) | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| JP5588865B2 (ja) * | 2007-07-31 | 2014-09-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトcd20に対するヒト抗体及びその使用方法 |
| US8940725B2 (en) * | 2010-05-31 | 2015-01-27 | Ono Pharmaceutical Co., Ltd. | Purinone derivative |
| US20140303191A1 (en) * | 2011-10-19 | 2014-10-09 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| US20130302274A1 (en) * | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
| BR112014012727B1 (pt) * | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
| WO2014081712A2 (en) * | 2012-11-20 | 2014-05-30 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with bruton's tyrosine kinase |
| KR20160013204A (ko) | 2013-05-30 | 2016-02-03 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료 |
| EP3076974A1 (en) | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| RS63364B1 (sr) | 2014-08-11 | 2022-07-29 | Acerta Pharma Bv | Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora |
-
2014
- 2014-11-04 CA CA2926893A patent/CA2926893C/en active Active
- 2014-11-04 RU RU2016122232A patent/RU2727650C2/ru active
- 2014-11-04 ES ES14796468T patent/ES2728350T3/es active Active
- 2014-11-04 NZ NZ718792A patent/NZ718792A/en unknown
- 2014-11-04 WO PCT/EP2014/073640 patent/WO2015067586A2/en not_active Ceased
- 2014-11-04 CN CN202110948035.8A patent/CN113995843A/zh active Pending
- 2014-11-04 KR KR1020167014779A patent/KR101874215B1/ko active Active
- 2014-11-04 PL PL14796468T patent/PL3066126T3/pl unknown
- 2014-11-04 EP EP14796468.8A patent/EP3066126B1/en active Active
- 2014-11-04 MY MYPI2016701617A patent/MY178726A/en unknown
- 2014-11-04 JP JP2016524505A patent/JP6478989B2/ja active Active
- 2014-11-04 CN CN201480061326.3A patent/CN105792846A/zh active Pending
- 2014-11-04 HK HK16111064.0A patent/HK1222803A1/zh unknown
- 2014-11-04 TR TR2019/07240T patent/TR201907240T4/tr unknown
- 2014-11-04 CN CN202210119724.2A patent/CN114632158A/zh active Pending
- 2014-11-04 US US14/532,247 patent/US20150125446A1/en not_active Abandoned
- 2014-11-04 MX MX2016005801A patent/MX374290B/es active IP Right Grant
- 2014-11-04 AU AU2014345712A patent/AU2014345712B2/en active Active
- 2014-11-06 AR ARP140104176A patent/AR098328A1/es unknown
- 2014-11-06 TW TW103138580A patent/TWI524899B/zh active
-
2016
- 2016-04-06 IL IL244960A patent/IL244960B/en unknown
- 2016-05-05 PH PH12016500839A patent/PH12016500839A1/en unknown
-
2019
- 2019-11-11 US US16/679,483 patent/US12186392B2/en active Active
-
2024
- 2024-11-25 US US18/958,224 patent/US20250205333A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ718792A (en) | Combination therapy of an anti cd20 antibody with a btk inhibitor | |
| MX389342B (es) | Un anticuerpo anti-cd20 en combinación con un inhibidor de bcl-2 y un inhibidor de mdm2 para usarse en el tratamiento de cáncer. | |
| AR096183A1 (es) | Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco | |
| MX2016015363A (es) | Terapias de combinacion para el tratamiento de cancer. | |
| MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
| MX378546B (es) | Combinaciones con anticuerpos anti-cd38 para usarse en el tratamiento de un sujeto que tiene una neoplasia maligna hematológica cd38-positivo | |
| GEP20217331B (en) | Anti-tigit antibodies | |
| CO2017001191A2 (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
| HUE065528T2 (hu) | Zanubrutinib kombinációja anti-CD20 vagy anti-PD-1 antitesttel rák kezelésében történõ alkalmazásra | |
| MX376078B (es) | Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer. | |
| PL2958945T3 (pl) | Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| CL2016001586A1 (es) | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 | |
| MX370597B (es) | Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer. | |
| MX2017005553A (es) | Terapia de combinacion para cancer. | |
| AR077866A1 (es) | Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina | |
| MX2016002974A (es) | Eteres de arilo y sus usos. | |
| PT2976360T (pt) | Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro | |
| MX2016002645A (es) | Tratamiento combinado para tratar el glioblastoma. | |
| MX2015014501A (es) | Terapia de combinacion de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd22-farmaco. | |
| AR077867A1 (es) | Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona | |
| PH12014501543A1 (en) | Combination therapy for the treatment of ovarian cancer | |
| CR20170537A (es) | Anticuerpos contra csf-1r humano para uso en la inducción de linfocitosis en linfomas o leucemias. | |
| MX2019003755A (es) | Regimen de dosificacion de avelumab para el tratamiento de cancer. | |
| EA201591304A1 (ru) | Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |